Motilal Oswal is bullish on Sanofi India has recommended buy rating on the stock with a target price of Rs 6930 in its research report dated May 07, 2019.
Motilal Oswal's research report on Sanofi India
Sales increased 16% YoY to INR7.2b (our estimate: INR6.8b) in 1QCY19. Gross margin shrank 250bp YoY to 57% due to the change in the product mix. However, EBITDA margin contracted at a much lower rate of 30bp YoY to 21.4% (our estimate: 20%), supported by lower other expenses (-110bp YoY to 21.2% of sales) and employee cost (-110bp YoY to 14.4%). Absolute EBITDA increased 14% YoY to INR1.6b (our estimate: INR1.4b). PAT grew 12.6% YoY to INR929m (our estimate: INR828m).
Outlook
We cut our CY19/20 earnings estimates by 5%/4.5% to factor in the lower gross margin and the higher tax rate. We roll our target price to a 12-month forward earnings basis and continue valuing SANL at 32x P/E to arrive at a price target of INR6,930 (prior: INR7,000).
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Read More
